ES2960686T3 - Células T reguladoras que expresan un receptor de antígeno quimérico - Google Patents

Células T reguladoras que expresan un receptor de antígeno quimérico Download PDF

Info

Publication number
ES2960686T3
ES2960686T3 ES19700530T ES19700530T ES2960686T3 ES 2960686 T3 ES2960686 T3 ES 2960686T3 ES 19700530 T ES19700530 T ES 19700530T ES 19700530 T ES19700530 T ES 19700530T ES 2960686 T3 ES2960686 T3 ES 2960686T3
Authority
ES
Spain
Prior art keywords
car
antigen
cells
treg
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19700530T
Other languages
English (en)
Spanish (es)
Inventor
Anna Nowak
Dominik Lock
Andrew Kaiser
Alexander Scheffold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Miltenyi Biotec GmbH
Charite Universitaetsmedizin Berlin
Original Assignee
Miltenyi Biotec GmbH
Charite Universitaetsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miltenyi Biotec GmbH, Charite Universitaetsmedizin Berlin filed Critical Miltenyi Biotec GmbH
Application granted granted Critical
Publication of ES2960686T3 publication Critical patent/ES2960686T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES19700530T 2018-01-19 2019-01-17 Células T reguladoras que expresan un receptor de antígeno quimérico Active ES2960686T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18152631 2018-01-19
PCT/EP2019/051143 WO2019141774A1 (en) 2018-01-19 2019-01-17 Regulatory t cell expressing a chimeric antigen receptor

Publications (1)

Publication Number Publication Date
ES2960686T3 true ES2960686T3 (es) 2024-03-06

Family

ID=61027458

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19700530T Active ES2960686T3 (es) 2018-01-19 2019-01-17 Células T reguladoras que expresan un receptor de antígeno quimérico

Country Status (8)

Country Link
US (1) US12178872B2 (https=)
EP (1) EP3740569B1 (https=)
JP (1) JP7720148B2 (https=)
KR (1) KR102795692B1 (https=)
CN (1) CN111684061B (https=)
CA (1) CA3088832A1 (https=)
ES (1) ES2960686T3 (https=)
WO (1) WO2019141774A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2960686T3 (es) 2018-01-19 2024-03-06 Miltenyi Biotec Bv & Co Kg Células T reguladoras que expresan un receptor de antígeno quimérico
JP7701908B2 (ja) * 2019-08-16 2025-07-02 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 抗ｃｄ３８キメラ抗原受容体を発現する制御性ｔ細胞
GB201912515D0 (en) * 2019-08-30 2019-10-16 King S College London Engineered regulatory T cell
EP4100027A1 (en) * 2020-02-04 2022-12-14 Miltenyi Biotec B.V. & Co. KG Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
CA3175039A1 (en) 2020-03-10 2021-09-16 Cellares Corporation Systems, devices, and methods for cell processing
JP2025524629A (ja) * 2022-07-11 2025-07-30 ソノマ バイオセラピューティクス， インコーポレイテッド 組み換えサイトカイン受容体及び使用方法
CN120897988A (zh) 2023-03-21 2025-11-04 赛阿瑞斯公司 用于在细胞处理系统内的电穿孔的系统、设备和方法
US12399193B2 (en) 2023-05-05 2025-08-26 Cellares Corporation Systems, devices, and methods for combined cell processes
EP4467155A1 (en) * 2023-05-23 2024-11-27 Fundación para la Investigación Biomédica del Hospital Gregorio Marañón (FIBHGM) Car-thytreg cells, compositions and uses thereof in immunotherapy
CN121752711A (zh) 2023-06-30 2026-03-27 赛阿瑞斯公司 用于自动化细胞处理系统内的流体转移的系统、装置和方法
US12305156B2 (en) 2023-08-21 2025-05-20 Cellares Corporation Systems, devices, and methods for fluid control in a cell processing system
WO2025041064A2 (en) 2023-08-21 2025-02-27 Cellares Corporation Systems, devices, and methods for automatic cell sorting
US12497587B2 (en) 2023-08-21 2025-12-16 Cellares Corporation Bioreactors and methods of their use in automatic cell processing systems
US12492368B2 (en) 2024-03-11 2025-12-09 Cellares Corporation Monitoring air pressure within a cell processing system
US12559710B2 (en) 2024-03-27 2026-02-24 Cellares Corporation Liquid level and flow rate detection within a cell processing system
USD1109621S1 (en) 2024-04-15 2026-01-20 Cellares Corporation Analytical platform for biological material testing

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
GB0420466D0 (en) * 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
WO2009072003A2 (en) 2007-12-07 2009-06-11 Miltenyi Biotec Gmbh Sample processing system and methods
DE102009040716B4 (de) * 2009-09-10 2011-07-14 Miltenyi Biotec GmbH, 51429 Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen
ES2791716T3 (es) 2010-12-14 2020-11-05 Univ Maryland Células T que expresan al receptor de antígeno quimérico antietiqueta universal y métodos para el tratamiento del cáncer
CN102153651B (zh) * 2011-01-21 2012-11-14 厦门大学 抗葡聚糖单链抗体及其制备方法
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
JP7372728B2 (ja) 2014-10-31 2023-11-01 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 改変ｔ細胞に関する方法および組成物
KR102768442B1 (ko) 2015-09-07 2025-02-17 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 CD8+CD45RClow TREGS의 신규한 아집단 및 이들의 용도
DK3368571T5 (da) 2015-10-30 2024-09-30 Univ California Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf
WO2017100428A1 (en) 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
JP2019508036A (ja) 2016-02-16 2019-03-28 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 免疫療法組成物及び方法
KR20190003938A (ko) 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
US20170274095A1 (en) * 2016-03-23 2017-09-28 The Board Of Trustees Of The Leland Stanford Junior University Enhanced regulatory t cells targeted to sites of inflammation with chimeric antigen receptors and expressing factors that enhance viability of pancreatic cells
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
EP3336107A1 (en) * 2016-12-15 2018-06-20 Miltenyi Biotec GmbH Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptor
CN107557342A (zh) * 2017-11-02 2018-01-09 广东万海细胞生物科技有限公司 一种CAR‑Treg 细胞的制备方法及其应用
ES2960686T3 (es) 2018-01-19 2024-03-06 Miltenyi Biotec Bv & Co Kg Células T reguladoras que expresan un receptor de antígeno quimérico
CN117693439A (zh) 2021-07-28 2024-03-12 伊顿智能动力有限公司 自适应可控车辆逆变器系统和方法

Also Published As

Publication number Publication date
US20200353004A1 (en) 2020-11-12
JP7720148B2 (ja) 2025-08-07
WO2019141774A1 (en) 2019-07-25
US12178872B2 (en) 2024-12-31
JP2021511041A (ja) 2021-05-06
KR20200113211A (ko) 2020-10-06
CN111684061B (zh) 2024-07-30
EP3740569A1 (en) 2020-11-25
CA3088832A1 (en) 2019-07-25
EP3740569B1 (en) 2023-07-26
CN111684061A (zh) 2020-09-18
KR102795692B1 (ko) 2025-04-16

Similar Documents

Publication Publication Date Title
ES2960686T3 (es) Células T reguladoras que expresan un receptor de antígeno quimérico
US20220281944A1 (en) Spycatcher and spytag: universal immune receptors for t cells
JP7262535B2 (ja) 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
US11041012B2 (en) Universal immune receptor expressed by T cells for the targeting of diverse and multiple antigens
EP3445787B1 (en) Compositions and methods for t-cell receptors reprogramming using fusion proteins
JP7109789B2 (ja) 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
JP2023029373A (ja) キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
US20190085063A1 (en) Compositions and Methods for Generating a Persisting Population of T Cells Useful for the Treatment of Cancer
BR112020005361A2 (pt) anticorpos anti-hla-a2 e métodos de uso dos mesmos
CN115768464A (zh) 产生工程化记忆样nk细胞及其组合物的方法
US20230103327A1 (en) Quantitative control of activity of engineered cells expressing spycatcher and spytag universal immune receptors
CN121568707A (zh) CAR-ThyTreg细胞、组合物及其在免疫疗法中的用途
WO2019139972A1 (en) T cell receptors for immunotherapy
HK1252643B (en) Compositions and medical uses for tcr reprogramming using fusion proteins